parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.23 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in breast hormone-responsive cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 1851

receipt 1859: EFHD1 in dopamine neurons, braak

power: full sample -0.08 (p 0.754, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.867, n 18). could be the mix.
skeptic: leave-one-out range -0.19 to +0.03, sign flips 2; without severely affected donors -0.08 (p 0.754, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EFHD1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 1858: EFHD1 in oligodendrocytes, braak

power: full sample -0.21 (p 0.403, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.23 (p 0.351, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.21 (p 0.408, n 18). could be the mix.
skeptic: leave-one-out range -0.39 to -0.11, sign flips 0; without severely affected donors -0.21 (p 0.403, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EFHD1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts